萊美藥業(300006.SZ):減少產業併購基金投資額 實繳出資額約1.14億元
格隆匯3月17日丨萊美藥業(300006.SZ)公佈,公司於2018年2月23日第四屆董事會第十一次會議審議通過了《關於投資設立產業併購基金的議案》,同意公司與瀘州錦淳股權投資中心(有限合夥)、瀘州老窖璞信股權投資基金合夥企業(有限合夥)、趙佳萍女士、石華燕女士共同投資設立瀘州久澤股權投資中心(有限合夥)(“合夥企業”、“產業併購基金”)。該產業併購基金總規模不超過4.31億元,公司認繳出資金額1.5億元。該產業併購基金已於2018年2月28日完成工商註冊登記手續。截止公告披露日,公司實繳出資額為約1.14億元。
為進一步聚焦主業,集中核心資源圍繞公司戰略發展規劃,打造甲狀腺疾病領域頭部企業,公司擬減少產業併購基金投資額。合夥企業召開了2020年第一次合夥人會議,經全體合夥人一致同意,瀘州久澤股權投資中心(有限合夥)認繳出資額由4.31億元減至約3.95億元,其中公司認繳出資額由1.5億元減至約1.14億元,其他合夥人認繳出資額保持不變。
此次減少產業併購基金投資額不會影響公司根據合夥協議約定的收益,不會影響公司的持續經營能力,有助於公司聚焦主營業務發展,不會對公司當期業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.